COLLISION RELAPSE Trial

Colorectal Cancer Clinical Trial

Official title:

COLLISION RELAPSE Trial - Recurrent Colorectal Liver Metastases: Repeat Local Treatment +/- Neoadjuvant Systemic Therapy - a Phase III Prospective Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05861505
• Other study ID #: NL78220.029.21
• Status: Recruiting
• Phase: Phase 3
• Start date: April 24, 2023
• Est. completion date: May 1, 2028

Study information

• Verified date: May 2023
• Source: Amsterdam UMC, location VUmc
• Contact: M Dijkstra
• Phone: +31(0)204444444
• Email: interventieradiologie[@]vumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM in the absence of extrahepatic disease.

Description:

Study design: The COLLISION RELAPSE trial is a prospective multicenter phase III randomized controlled trial. The primary conducting center will be the Amsterdam UMC (Amsterdam, the Netherlands). We hypothesize that neoadjuvant systemic therapy followed by repeat local treatment is superior to upfront repeat local treatment for the selected patient groups in terms of the primary objective (OS). The Cox proportional hazards model (1-sided; superiority) and the PASKWIL criteria for adjuvant treatment for the benefit of OS from the Dutch Society of Medical Oncology are used for the sample size calculations. A total number of 360 patients will be randomized (NR) into one of two arms: arm A (control group) upfront repeat local treatment (n=180) and arm B (intervention group) 12 weeks of neoadjuvant systemic therapy followed by repeat local treatment (n=180).

Study population: Patients with a maximum of 5 recurrent new locally treatable CRLM within 12 months after initial curative intent local treatment of CRLM, no extrahepatic disease, and a good performance status (ECOG 0-2) are considered eligible. Both chemo-naïve patients and patients who did not progress on either oxaliplatin or irinotecan chemotherapy prior to the initial local treatment are eligible for inclusion.

Eligible patients will be stratified before randomization into two groups depending on the interval between initial local treatment and first detection of recurrent CRLM: recurrence within 6 months and recurrence between 6 and 12 months, RAS/BRAF mutation vs RAS/BRAF wildtype, prognostic risk score (low vs high risk, clinical risk score Fong et al. (83)) and previous chemotherapy versus no previous chemotherapy.

Intervention: Eligible patients will be randomized into one of two arms: arm A (control group) upfront repeat local treatment and arm B (intervention group) 12 weeks of neoadjuvant systemic therapy followed by repeat local treatment. Patients in arm B will receive maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation. Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 360
• Est. completion date: May 1, 2028
• Est. primary completion date: May 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

• Age >18 years

• Good performance status (ECOG 0-2 // ASA 1-3)

• Histological documentation of primary colorectal tumor

• Local treatment performed for initial CRLM

• New recurrence =12 months

• =1 locally treatable CRLM (resectable* and/or ablatable)

• Total number of new CRLM =5

• Chemo-naïve or history of response to CAPOX/FOLFOX/FOLRIRI

• Life expectancy of at least 12 weeks

• Adequate bone marrow, liver and renal function

• Written informed consent Exclusion criteria

• Extrahepatic disease

• MSI/dMMR

• Radical local treatment unfeasible or unsafe (e.g. insufficient future liver volume)

• Compromised liver function (e.g. signs of portal hypertension, INR > 1,5 without use of anticoagulants, ascites)

• Uncontrolled infections (> grade 2 NCI-CTC version 3.0)

• Pregnant or breast-feeding subjects

• Immuno- or chemotherapy = 6 weeks prior to the randomization

• Severe allergy to contrast media not controlled with premedication

• Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results

ECOG = Eastern Cooperative Oncology Group, ASA = American Society of Anesthesiologists, MSI = Microsatellite instability, dMMR = deficient mismatch repair

• Resection for resectable lesions considered possible obtaining negative resection margins (R0) and preserving adequate liver reserve

Related Conditions & MeSH terms

• Chemotherapy Effect
• Colorectal Cancer
• Liver Metastases
• Liver Metastasis Colon Cancer
• Liver Neoplasms
• Neoplasm Metastasis
• Neoplasms, Second Primary
• Recurrence
• Surgery

Intervention

Drug:
• Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)
Standard first line systemic treatment: CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks) Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation

Other:
• Repeat local treatment
Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis. The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation). The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection).

Locations

Country	Name	City	State
Netherlands	Amsterdam UMC	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
Amsterdam UMC, location VUmc

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival (OS) per patient	Primary objective is to compare overall survival (OS) in both study arms, counting from the date of randomization to the date of death of the patient or to the last day of follow-up (censored).	5 years
Secondary	Distant progression-free survival (DPFS) per patient	Distant progression free survival (DPFS; per patient analysis): Overall DPFS is defined as the time from randomization to the time of disease progression (according to the RECIST 1.1 guideline) or cancer related death (events), death related to other causes is considered a competing risk	5 years
Secondary	Local tumor progression-free survival (LTPFS) per patient and per tumor treated	Local tumor progression free survival (LTPFS; per tumor and per patient analysis): Overall LTPFS is defined as the time from randomization to the time of local disease progression, new metastases (events), censoring the date of death from any cause (competing risk), completion ablations performed within 6 weeks for residual tumor are not considered events for the local tumor progression analysis	5 years
Secondary	Systemic therapy related toxicity per patient following neoadjuvant systemic therapy	Systemic therapy related toxicity is graded from 1 to 5 according to the CTCAE version 5.0	5 years
Secondary	Procedural morbidity and mortality per patient following repeat local treatment	Procedural morbidity and mortality are graded from I to V according to the standard classification of surgical complications	5 years
Secondary	Length of hospital stay per patient following repeat local treatment	In days	5 years
Secondary	Assessment of pain per patient	- Pain assessment using visual analogue scale questionnaires (VAS; per procedure analysis: Assessed prior to, directly after and every three months after local treatment;	5 years
Secondary	Quality of life (QoL) per patient	- To determine quality of life in both treatment arms. Quality of life assessment using EORCT QLQ-C30, EQ-5D, and PRODISQ questionnaires (per procedure analysis): Assessed prior to, and every three months after local treatment, assessed prior to, during and after neoadjuvant systemic therapy	5 years
Secondary	Quality-adjusted life years (QALY) per patient	- Quality-adjusted life years (QALY) per treatment arm (per patient analysis).	5 years
Secondary	Cost-effectiveness ratio (ICER)	- Direct and indirect total costs of care per treatment arm, and incremental cost-effectiveness ratio (ICER)	5 years